ArticleObesity surgery2026
Impact of Prior COVID-19 Infection on Renal Outcomes after Roux-en-Y Gastric Bypass: A 12-Month Prospective Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and SARS-CoV-2 infection have both been associated with renal injury through inflammatory, endothelial, and microvascular mechanisms. Whether a history of COVID-19 modifies renal trajectories after metabolic surgery remains unclear.
objectiveTo evaluate the association between prior COVID-19 infection and renal outcomes 12 months after laparoscopic Roux-en-Y gastric bypass (LRYGB).
methodsWe conducted a prospective cohort study including 38 adults with severe obesity (BMI ≥ 35 kg/m² with comorbidities or ≥ 40 kg/m²) and preserved baseline kidney function who underwent LRYGB between January 2022 and January 2024. Participants were stratified according to a history of laboratory-confirmed COVID-19 infection. Renal outcomes included measured and estimated glomerular filtration rate, creatinine and urea clearance, 24-h proteinuria, albuminuria, and urine albumin-to-creatinine ratio (ACR). KDIGO combined G/A risk categories were assessed at baseline and 12 months. Longitudinal changes were explored using within-group analyses and between-group comparisons of trajectories.
resultsEighteen patients (47%) had a history of COVID-19 infection. Weight loss and metabolic response were comparable between groups (BMI 44 ± 6 to 29 ± 5 kg/m²; p < 0.01). Classical renal function parameters remained stable in both groups. ACR decreased significantly over time only among patients without prior COVID-19 infection (14 ± 14 to 7 ± 6 mg/g; p = 0.03), whereas the reduction did not reach statistical significance in previously infected patients (12 ± 10 to 10 ± 10 mg/g; p = 0.20). However, formal between-group analyses did not demonstrate a statistically significant difference in renal trajectories.
conclusionsLRYGB was associated with substantial weight loss and stable renal function at 12 months regardless of prior COVID-19 infection. A differential within-group pattern in albuminuria improvement was observed, but between-group differences were not statistically significant. These findings should be interpreted as exploratory and hypothesis-generating, highlighting the need for larger studies with longer follow-up and mechanistic biomarkers to clarify renal outcomes after metabolic surgery in patients with a history of COVID-19 infection.
Indexed as
Identifiers
41680560What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.